Datapoint: Jardiance Catches Up With Farxiga in Heart Failure
August
24
The FDA last week approved Eli Lilly and Boehringer Ingelheim’s SGLT2 inhibitor Jardiance for the treatment of heart failure in patients with reduced ejection fraction, regardless of diabetic status. Jardiance is the second SGLT2 inhibitor to snag this indication, behind AstraZeneca’s Farxiga. For the treatment of chronic heart failure under the pharmacy benefit, Farxiga holds covered or better status for 92% of all insured lives.
SOURCE: MMIT Analytics, as of 8/23/21
© 2024 MMIT
Meet Our Reporters
-
Jill Drachenberg Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jill Drachenberg's Profile -
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
